Pharnext to reinforce equity capital by conversion of convertibles bonds
Pharnext to host a KOL investors event focused on CMT in Paris (only availbable in French)
PXT3003: FDA Fast Track designation for the treatment of CMT1A
Pharnext raises €15 million without discount
PXT3003: Early therapeutic effects in a transgenic rat model of CMT1A
Susanne Dorn and Serge Fitoussi appointed as Chief Regulatory Officer and Chief Medical Officer
Pharnext to present at BMO 2018 Prescriptions for Success Healthcare Conference
Pharnext announces 2018 half-year results
PXT3003: Positive topline results from pivotal Phase 3 trial for treatment of CMT1A
Pharnext and Vitaccess launch International CMT&Me Observational Study
David Stout joins Pharnext’s Board of Directors
Pharnext to host a key opinion leader symposium focused on CMT1A
Pharnext announces issuance of composition of matter patents covering PLEODRUG™ PXT3003 and PXT864
PXT3003: EMA agrees with Pharnext’s pediatric investigation plan
PXT3003: Top-line results from Phase 3 trial in CMT1A by October 2018
PXT3003: Granted priority review by the China FDA
Pharnext announces €20,5 million bond loan
Pharnext to present latest data on its two lead assets at several international scientific conferences
Pharnext transfers its liquidity contrat (only available in French)
Pharnext appoints Amit Kohli as Chief Operating Officer
Pharnext to showcase PLEOTHERAPY™ R&D platform at the Global Orphan Drug Conference
Pharnext confirms its continued eligibility to the PEA-PME (only available in French)
Pharnext reports financial results for Year-End 2017
Pharnext successfully raises €16 million via private placement
Pharnext to present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference
Pharnext to attend Shareholders meetings in Bordeaux and Lyon (only in French)
Pharnext to attend Shareholders meeting in Paris (only in French)
PXT3003: Status of ongoing Phase 3 trial to be featured at the Francophone Peripheral Nerve Society conference
Philippe Chambon joins Pharnext’s Board of Directors
PXT3003: Successful intermediate analyses for Phase 3 trial in CMT1A
Page 1 of 3
